Pipeline

Multiple near-term regulatory and pivotal-trial milestones

Two late-stage assets entering regulatory and pivotal-trial phase with established safety, biomarker validation, and pediatric rare disease positioning.

*Estimated dates subject to change – See “Forward-Looking Statements”